Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent Research Progress
As a member of the CaMK family, Ca2+/calmodulin-dependent kinase kinase (CAMMK2) phosphorylates Ca21/CaM-dependent protein kinase 1 (CaMKI), Ca21/CaM-dependent protein kinase 4 (CaMKIV), and adenosine monophosphate activation of protein kinase (AMPK) in response to increased intracellular Ca21 (Fig. 1). Regulation of CaMKI and/or CaMKIV by CAMMK2 regulates cell cycle progression, cell motility, survival, and gene transcription. In addition, CAMMK2 also affects hypothalamus, adipocytes differentiation, energy homeostasis of macrophage function, as well as lipid and carbohydrate metabolism in the liver. It has been reported that abnormal expression of CAMMK2 was associated with a variety of cancers.

Figure 1. Schematic of the CaMK signaling pathway and pharmacological inhibitors that target each component. (Lin, et al. Hepatology, 2015)
CAMMK2 and HCC
Hepatocellular carcinoma (HCC) accounts for nearly 80% of all liver cancers and represents significant health risks. Recent studies have found that CAMMK2/CaMKIV relay is an upstream regulator of the oncogenic mammalian target of rapamycin/ribosomal protein S6 kinase, and the importance of this CAMMK2/CaMKIV axis in HCC growth is confirmed by the potent growth inhibitory effects of genetically or pharmacologically decreasing CAMMK2 activity; in summary, these findings indicate that CAMMK2 and CaMKIV may represent potential targets for hepatic cancer.
CAMMK2 and glioma
Glioma refers to a tumor originating from glial cells and is a common primary intracranial tumor. Studies have found that up-regulation of CAMMK2 in high-grade glioma samples was associated with promoter hypomethylation. Increased expression of CAMMK2 is associated with poor prognosis. By in vitro experiments, it has been demonstrated that CAMMK2 can promote cell migration, invasion and proliferation. In conclusion, the expression level of CAMMK2 can be regulated by promoter methylation. CAMMK2 may serve as a prognostic marker for gliomas and may be a potential therapeutic target for gliomas.
CAMMK2 and Gastric cancer
Gastric cancer is one of the most common malignant tumors of the gastrointestinal tract and is associated with poor prognosis. Subbannayya et al. found that CAMMK2 was 7-fold overexpressed in gastric tumor tissues. Immunohistochemical labeling of tumor tissue microarrays used to validate CAMMK2 overexpression showed that it was indeed overexpressed in 94% of gastric cancer cases. Silencing CAMMK2 with small interfering RNA (siRNA) significantly reduced cell proliferation, colony formation and invasion of gastric cancer cells. The results indicate that CAMMK2 signaling in gastric cancer via AMP-activated protein kinase (AMPK) activation suggests that CAMMK2 may be a novel therapeutic target for gastric cancer.
CAMMK2 and PCa
Prostate cancer (PCa) is the second most common malignant tumor in men worldwide. Recently, CAMMK2 was identified as a target gene for miR-224. Studies have shown that forced expression of miR-224 can inhibit PCa cell proliferation and cell cycle by regulating the expression of CAMMK2 in vitro. Furthermore, the expression level of miR-224 in PCa tissue was significantly negatively correlated with the expression level of CAMMK2 mRNA. In addition, combined low miR-224 expression and high CAMMK2 expression (miR-224-low/CAMMK2-high) was closely associated with advanced clinical stage. Furthermore, PCa patients with high expression of miR-224-low/CAMMK2-more frequently had shorter overall survival than the group with other expression patterns of two molecules. In summary, the current data provide compelling evidence that miR-224 and its target gene CAMMK2 may act synergistically on the malignant progression of PCa. The combined detection of miR-224 and CAMMK2 expression represents an effective predictor of patient prognosis and can be a novel marker that can provide additional prognostic information in PCa.
In conclusion, CAMMK2 plays an important role in the development of various cancers. Therefore, further exploration of the role of CAMMK2 in the mechanism of cancer development will provide new insights into the diagnosis and treatment of cancer.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.